In a move to strengthen its oncology pipeline, pharmaceutical giant Gilead Sciences has entered into an agreement to acquire RP-3467, a specialized drug candidate from Repare Therapeutics. This strategic acquisition occurs as Repare prepares for a complete corporate transition.
Transaction Details and Financial Impact
-
Deal Value: Gilead will provide an upfront payment of $25 million. An additional $5 million is tied to the successful completion of technology transfer activities, bringing the total consideration to $30 million.
-
Shareholder Benefits: The cash infusion from Gilead has bolstered Repare’s reserves. Consequently, the estimated payout for Repare shareholders under the pending merger with XenoTherapeutics has been revised upward to approximately $2.20 per common share.
Scientific Significance of RP-3467 RP-3467 is a potent small-molecule inhibitor of Polθ (Polymerase theta), an enzyme central to the concept of synthetic lethality.
-
Mechanism: The inhibitor targets cancer cells harboring BRCA mutations or other specific genomic alterations. By blocking the cell’s DNA repair pathway, it forces malignant cells into programmed cell death.
-
Potential: The candidate is positioned as a potential best-in-class Polθ ATPase inhibitor, now backed by Gilead’s extensive global infrastructure in oncology research and development.
Source: https://www.worldpharmaceuticals.net/news/gilead-sciences-to-acquire-repares-rp-3467/